Dextera Biosciences logo

Dextera Biosciences jobs and careers

About Dextera Biosciences

Dextera Biosciences is developing a new category of drugs, Synthetic D-Proteins, to overcome the limitations of current drug modalities. Synthetic D-Proteins exhibit antibody-like specificity to a single therapeutic target but with the broad distribution of small molecules, all while being otherwise “invisible” to the rest of the body. The consequences are that we can deliver sustained antibody-like activity specifically to interstitial targets, enable oral delivery with complete metabolic stability, and extend therapeutic durability with no immunogenicity. We are focusing on debilitating diseases where significant unmet need remains due to the limitations of current drugs.

Employees
11 to 50

Leadership

The top of Dextera Biosciences's org chart, with how many people report into each leader.

GWPhoto of Greg Went

Greg Went

Chief Executive Officer And Chairman

4 reports

KLPhoto of Kyle Landgraf

Kyle Landgraf

VP, Discovery Biology

1 report

JWPhoto of Julia Williams

Julia Williams

Director Of Finance

SCPhoto of Sarah Chapman

Sarah Chapman

Corporate Strategy Advisor